Abstract. Despite sophisticated intensive medicine, between one and three malaria-associated deaths occur annually in Switzerland. In this retrospective study, 33 deaths (25 men and 8 women) caused by falciparum malaria reported in Switzerland from 1988 to 2002 were analyzed. The case fatality ratio (CFR) for the falciparum infections for the 15-year period was 1.2%, with a peak of 2.2% in 1991. Sub-Saharan Africa was the source of all the imported fatal infections. Non-immune Europeans had a significantly higher case fatality ratio than the non-Europeans (1.7% versus 0.2%; P < 0.001). Careless use or non-use of prophylaxis, sometimes because of physicians giving unsatisfactory pre-travel advice, and initially missed diagnosis post-travel were factors that contributed to the development of severe infections leading to death. Travelers should be sensitized to the risk of malaria by well-informed general practitioners. Updated information is readily available (www.safetravel.ch). Regarding diagnosis and treatment, greater physician awareness of the disease is needed, and expert advice should be sought without hesitation. Rapid malaria tests may be a useful diagnostic adjunct in centers where microscopic expertise is lacking. Falciparum malaria in a non-immune patient is an emergency requiring immediate treatment.
INTRODUCTION
Malaria is not endemic in Switzerland, and reported cases are usually imported by travelers or immigrants. Plasmodium falciparum is the predominant and most dangerous of the malaria species. Its widespread prevalence, high hospitalization rate, and potentially rapid and lethal course explain why malaria is one of the most important diseases in travelers. The realistic main goal of malaria prevention in Switzerland is to avoid falciparum infections and deaths. In this retrospective survey, the deaths caused by falciparum malaria reported in Switzerland from 1988 to 2002 were analyzed in their context to find out the circumstances that resulted in the fatal outcomes of these cases.
MATERIALS AND METHODS
In Switzerland, notification of malaria cases is mandatory, and the current reporting system was created in 1974. In 1988, the system was revised, and the reporting forms were slightly modified. The discussion about this raised the attention of the physicians to the notification system, and in the years after 1988, a consistently higher number of cases were reported annually and more detailed data were collected. Therefore, and for homogeneity reasons, the 15-year period from 1988 to 2002 was chosen for this study.
Usually, malaria is diagnosed both by physicians and laboratories. They report the cases on standard notification forms. Within 1 week, physicians have to complete a supplementary form with more detailed questions regarding the geographical origin of the infection, the use of chemoprophylaxis, and the progression of the disease (this form can be downloaded in French [http://www.bag-anw.admin.ch/infreporting/forms/d// malaria_d.pdf] and German [http://www.bag-anw.admin.ch/ infreporting/forms/d//malaria_d.pdf]. All data are transferred to the Swiss Federal Office of Public Health (SFOPH) to be registered into a database, regularly analyzed, and published as government reports in updates and annual bulletins (http:// www.bag.admin.ch/themen/medizin/00682/00684/01086/ index.html?lang‫ס‬de, German; http://www.bag.admin.ch/ themen/medizin/00682/00684/01086/index.html?lang‫ס‬fr, French). These data were the basis of this study. Independently, all deaths are reported through death certificates sent to the Swiss Federal Office of Statistics (SFOS). In some situations, only the SFOS was notified, and in these cases, little epidemiologic data were available.
In a second step, hospitals in which fatal cases happened were contacted. The case histories, clinical records, and interviews with some of the concerned physicians provided large and detailed data of many of the fatal cases.
The detailed data on the fatal cases were analyzed, interpreted, and compared with the results and conclusions from the analysis of the basic data from the SFOPH. Statistical analysis was performed using the Mann-Whitney U test, and significance was defined as P Յ 0.05 (two-tailed). In this study, all mixed infections notified to the SFOPH were considered as falciparum infections if one of the species was P. falciparum.
RESULTS
In the 15 years from 1988 to 2002, a total of 4,600 malaria cases and 33 deaths were reported to the SFOPH (Table 1) . Two thousand eight hundred seventy-one (62.4%) of the infections were caused by P. falciparum, and this species was responsible for all of the 33 deaths; in two cases, there was co-infection with P. vivax and P. malariae, respectively.
The case fatality ratio (CFR) of 1.2% for the falciparum infections is the result of quite different CFRs of two subgroups: the Europeans, mostly white non-immune people, and the non-Europeans, including a large number of immigrants from endemic countries. The fatality ratio of the Europeans (27/1,610, 1.7%) was significantly (P < 0.001) higher than the CFR calculated for the non-Europeans (2/970, 0.2%), explaining why the large and increasing proportion of African nationals among the falciparum cases does not contribute much to the deaths ( Table 2) .
The proportion of falciparum cases in the imported malaria data is increasing, because of the growing number of infections imported from Africa. Falciparum cases imported from other continents are several-fold fewer and are decreasing despite the even larger and increasing numbers of tourists visiting these areas ( Table 3 ). The increasing proportion of falciparum infections imported by African nationals from African countries is the reason for this trend among falciparum cases. In contrast, there was a decline in the number of cases imported by Swiss nationals. Table 4 shows an overview of the fatal cases that were notified during the observation period. This collective consisted of 25 (75.8%) men and 8 (24.2%) women. The mean age was 51.6 years (range, 26-80 years; outlier: 4-year-old girl), which is 10-15 years above the annual means of ages for falciparum cases in 1988-2002. Only two deaths of nonEuropeans were notified. Both of them, a 35-year-old man from Ghana and a 4-year-old girl from former Zaïre, were visiting relatives in their country of origin (so-called visiting friends and relatives [VFRs] ). The other imported infections were acquired by Europeans, mostly traveling as tourists. Sub-Saharan Africa was the source of all the imported infections, and Kenya was by far the most visited country among them (15/25, 60%). Travel duration was known for 18 of the cases. The mean travel duration was 14 days, and all travel was in the range of a short-term stay in the endemic countries (range, 2-30 days). Chemoprophylaxis was either not taken at all (16/19, 84 .2%) or on an irregular basis (2/19), which means that these travelers either took a drug that was not recommended in that situation or a recommended drug but did not take it properly or discontinued the prophylaxis. The 4-yearold girl traveling to former Zaïre used a chemoprophylaxis with chloroquine/proguanil in 1996, when mefloquine was considered to be more efficacious and was recommended also for children > 5 kg. However, if there was a contraindication against mefloquine (which is not known), chloroquine/ proguanil was recommended as a second choice at that time. At least two travelers had been prescribed mefloquine by their general practitioners but did not take it. A 52-year-old woman traveled to Kenya without chemoprophylaxis after a fatal misunderstanding with her general practitioner, although she was aware of the risk of malaria.
The median duration between arrival in Switzerland and symptom onset was 7 days (interquartile range, 10-3 days; 13 cases), although this onset can be much delayed, as illustrated by the case of the 56-year-old man returning from Togo 2001 who fell ill no less than 55 days after his return to Switzerland. The median duration from symptom onset until the establishment of the correct diagnosis (patient's and doctor's delay) was 5 days (interquartile range, 6.0-3.75; 20 cases). Because the notification forms do not separate out these two different kinds of delays, it was often difficult to identify them sepa- rately with precision, but in many of the case histories, we found typical patterns of mistakes and delays from both patients and doctors. An example for a prolonged delay is the case of the 52-year-old man who traveled to Mombasa, Kenya, in 2002. He used to travel twice a year to Africa for 20 years and thought that he was not at risk for malaria. Although he suffered from continuous vomiting and diarrhea for 4 days before returning to Switzerland, he hesitated 7 days before seeking medical help, and when admitted to the hospital, he was in a very poor condition and died the same night.
As for the doctor's delay, we could observe that in 12 of 15 cases (80%) with that specific data, the correct diagnosis was initially missed, mostly interpreted as harmless viral syndromes, but without ruling out malaria as a differential diagnosis. A rapid test was only performed in two cases. At least six of these patients were dismissed with a wrong diagnosis and died within a maximum of 4 days at home without seeing another doctor. Thirteen of these 15 patients (87%) sought help from their general practitioner, presenting mostly with flu-like symptoms such as fever, malaise, muscle aches, and chills. A 27-year-old flight attendant presented to a travel health practitioner and was immediately admitted to hospital, whereas a 51-year-old woman directly presented at the hospital with an orbital hematoma after she fell at home. She had been to Kenya 2 weeks before, and when she deteriorated, P. falciparum was found accidentally in a routine blood control. With the often rapid development of severe malaria, various vital organs are affected, and the patients usually are admitted to the intensive care unit ( Table 5 ). The median duration of symptomatic infection (symptom onset -death) was 8 days (interquartile range, 10.0-5.5; 23 cases).
Because there are so many parallels within the cases, and this is an important point in this study, we chose the case of the 49-year-old man who used to travel for many years to Kenya to show these common features of the fatal cases: 10 days after his return to Switzerland in January 1998, he started to feel ill with rhinitis and dry cough and later developed malaise and chills; 2 days after symptom onset, he saw his general practitioner, who sent him home with a suspected viral syndrome. The same evening, the family noticed a worsening of his mental state of the now anxious, confused, and dysarthric patient and brought him to a regional hospital. In a thick blood smear, malaria parasites were found but were not attributed to P. falciparum. The clinical charts gave no information of whether a thin blood smear was examined. Expert advice was not sought immediately, and treatment with antimalarials was not initiated because the patient seemed to recover while being treated with antibiotics against pneumonia. He claimed to have taken a regular chemoprophylaxis with mefloquine, but in a later examination, the plasma level of the drug was zero. After 2 days at the hospital, expert examination of the blood revealed parasitemia of 50% with P. falciparum. On the same day, the condition of the man worsened rapidly, he was transported to a larger hospital, and died the next day of multiple organ failure.
Apart from the imported cases, two persons acquired infection in Switzerland, namely a 53-year-old man, who lived near the international airport of Geneva and probably was bitten by a mosquito brought by plane from an endemic area in July 1996, and a 70-year-old man, who was found to have acquired a falciparum infection after he received large amounts of blood products in the context of two operations in 1999.
1,2 From 1988 to 2002, a total of 11 cases with unusual transmission were notified, that is, eight cases of odyssean, two cases of induced, and one case of congenital falciparum malaria. Because there were two deaths in this category, the calculated CFR was high (18.2%).
DISCUSSION
In our view, there are three principal findings of this study: First, imported falciparum malaria is still so frequent in Switzerland that every general practitioner is likely to be confronted with this dangerous parasite, and infections are associated with between one to three deaths per year. Second, patients can be separated in two subgroups: the Europeans, mostly traveling as tourists and with a high CFR, and the non-Europeans, mainly African nationals, running a significantly lower risk to die of malaria, but who are responsible for the growing number of imported falciparum infections from Africa because they tend to underestimate the risk of infection when their semi-immunity quickly wanes while living in Switzerland. Third, after examining the clinical records of the fatal cases, we pinpointed the key role of the general practitioners to prevent deaths because they can influence the be- havior of the traveler (before, during, and after travel) and are crucial for rapid diagnosis and treatment. When analyzing fatal cases caused by falciparum malaria, almost every case is a complex entity of factors leading to infection and death. This study clarified what these decisive factors were, the circumstances that contributed to the deaths, and how these fatalities could have been prevented. This global approach seems to be at the same time a strength and a weakness of this study. This is a strength because the examination of all data about the fatal cases of these years went beyond a case report and allowed the identification of the most important key events Pulmonary edema/ARDS. In at least two cases, fluid management of the dehydrated patient was extremely difficult because of the strong tendency to develop pulmonary edema. Renal 50% Acute renal failure. Cardiovascular 38% Cardiac arrest, circulatory collapse (twice associated with secondary bacteriological infection). In a patient that was treated with high doses of catecholamines and quinine for days, a complicating fatal myocarditis was diagnosed in the end. Two patients died of a pulmonary embolism. Other 25-100% Hematologic (severe anemia, thrombocytopenia, bleeding, disseminated coagulation, jaundice) and metabolic (hypoglycemia, acidosis) disorders as well as high fevers and dehydration could be found throughout the cases. Secondary infections were found in at least six cases (25%). 
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M 33 D Ghana, Nigeria None n/a n/a n/a 1993 F 62 CH S. Africa, Botswana Fansidar, not taken n/a n/a n/a 1994 F 60 CH Kenya, Uganda Fansidar, irregular −3 ¶ 9 68 ¶ 1994 M 46 CH n/a n/a n/a n/a n/ associated with these fatal outcomes. This is a weakness because, with such a broad approach, it is impossible to provide statistically significant evidence about many of the conclusions we drew that go deeper into the complex mechanisms of traveler's malaria than just morbidity and mortality. This needs a much more specific approach and appropriate data collection from the beginning other than that used in this retrospective study. There is no statistical evidence in our study that, for example, the patients who died of malaria had poorer pre-travel advice, longer patient's delays, or more missed diagnosis than the others. The calculated CFR of 1.2% for falciparum infections is comparable with the average CFRs reported from other countries of Europe in these years. 3, 4 However, comparing the CFRs in different countries can be difficult, because different notification systems and profiles of patients can strongly affect these values. Furthermore, in addition to some under-reporting in Switzerland, many infections in Swiss nationals or residents are diagnosed and treated in foreign and endemic countries without being reported to the SFOPH and do not appear in our statistics. 5 Non-immune Europeans traveling as tourists accounted for almost all of the deaths, and severe infection and fatalities among this group remain a regular event. Fortunately, this group has a slightly decreasing trend. The non-Europeans had a significantly lower CFR than the Europeans. This might be because, due to their acquired semi-immunity, the inflammatory response to the parasite is limited and the disease is less severe (clinical immunity), and they often have lower parasitemic levels than those recorded in non-immune travelers (anti-parasite immunity). However, many of them are not aware that this semi-immunity wanes quickly when they are not exposed to mosquito bites in Switzerland. An Italian study identified these patients, mostly traveling to their countries of origin to VFRs as a high-risk group for malaria infections because they tend to underestimate the risk of infection and rarely take any chemoprophylaxis. 6 We observed that, in Switzerland from 1988 to 2002, the number of falciparum malaria cases in migrants steadily increased.
The mean age of the fatal cases exceeded the annual means by 10-15 years, which is in line with a recent study that identified age as a risk factor for fatal outcome of falciparum malaria. 7 All imported infections were acquired in Sub-Saharan Africa, particularly in Kenya. This and generally the very few numbers of notified falciparum infections imported from outside the African continent show the lower risk in areas besides Africa-except some high risk regions-as well as the appropriateness of the current Swiss prevention strategies for all these areas, including the recommendation of emergency stand-by-emergency treatment (SBET) for low-risk areas.
Typical patterns and key events were found in the case histories that were associated with fatal outcome involved both travelers and physicians.
Even if in many cases the reasons for not taking or discontinuing chemoprophylaxis was not known, it is remarkable that none of the travelers in our study performed a correct and recommended prophylaxis (except the 4-year-old girl who used a second-choice drug). General practitioners should acquaint travelers with the disease and be in a position to provide travelers with clear and balanced information about anti-malarial drugs and mosquito bite protection. In 1997, a study regarding German and Swiss general practitioners concluded that many of them gave incorrect or unsatisfactory pre-travel advice deviating from the current recommendations, leading to misunderstandings and confusion, with the consequences that prescribed drugs are not taken or discontinued prematurely. 8 Current information on the recommendations is readily available (www.bag.admin.ch/infekt/reise/f [French], www.bag.admin.ch/infekt/reise/d [German], or www.safetravel.ch) and is also comprehensible and recommended for the informed traveler. Travelers who do not seek medical advice rely mainly on recommendations of travel operators, friends, or experiences, and often drugs that are no longer up-to-date and less efficacious are taken. They are often unaware or have a false perception of the tolerability profiles of anti-malarial medications. 9 General practitioners should be aware that they can greatly influence opinions about anti-malarial drugs in the population. 10 It is also very important to advise the traveler how to react in case of illness after the return, because this will reduce the patient's delay.
After infection, the first symptoms appeared on average 8 days (median, 6 days) after arrival in Switzerland. Physicians should question febrile patients about travel history. Early symptoms are very unspecific and not often not indicative of malaria or severe illness. This may also be a reason why patients often did not quickly seek medical help unless they had been instructed so earlier. In some cases, this led to extreme patient's delays.
Most patients presented first to a general practitioner, and the diagnosis was initially very often missed. Frequently, the symptoms were ascribed to flu-like viral syndromes. Sudden deterioration is not a rare event in falciparum malaria and dismissing febrile patients with a travel history that includes a sojourn in malaria-endemic areas without thinking of and ruling out this potentially lethal infection can be fatal. Once the suspicion of a possible falciparum malaria is raised, the general practitioner should clarify the exact (species) diagnosis and the clinical assessment of the state of health of the patient.
The microscopic diagnosis is made by analyzing thick (detection of parasitemia) and thin (species identification) blood films. The detection of parasites can be very time-consuming, especially in cases with low parasitemia, and identifying the plasmodia species can be a very difficult task. Delayed recognition of P. falciparum led, at least in one of the fatal cases, to an important delay of appropriate treatment. Therefore, the microscopical diagnosis should be done or at least confirmed by an expert laboratory as fast as possible, at least within 12 hours. One single negative result does not rule out falciparum malaria, and blood analyses should be repeated after 12-24 hours. For an immediate laboratory assessment, physicians can use falciparum rapid tests as a helpful tool, using a positive test result as a positive predictor for infection. A recent meta-analysis has shown that rapid malaria tests are useful in the assessment of febrile travelers returning from Sub-Saharan Africa 11 with the probability of P. falciparum malaria estimated at 97% (CI, 92-99%) after a positive test result. However, here also, blood should be brought or sent to an expert laboratory, and one negative rapid test result does not rule out falciparum malaria. A study in 2002 showed that, if the clinical suspicion is high but microscopy is still delayed or negative, there are clinical and laboratory predictors that fully justify presumptive anti-malarial treatment. 12 The strongest predictors for malaria infection in that study were enlarged spleen (clinically assessed) and thrombocytopenia.
Regarding the state of health of the patient, every physician should bear in mind that severe falciparum malaria can be a sudden, life-threatening event. If falciparum malaria is suspected and the patient is in a bad state of health, he must be hospitalized, and a specialist in travel or tropical medicine should be immediately consulted.
The median delay of 5 days between the onset of symptoms and the establishment of the correct diagnosis is in line with other observations with P. falciparum. 13, 14 Ideally, these delays could be reduced to 1 or 2 days, if the patients would seek immediately help in case of illness after travel and if physicians were more aware of the disease and did not miss the diagnosis. The median of 8 days that remained for the patients to live after the symptom onset (and so only a median of 3 days from the correct diagnosis until death) suggest that the patients were already in an advanced disease stage when correctly diagnosed and treated. Once severe malaria had developed, various vital organs were often affected, and even optimal intensive care did not prevent fatal outcome. The difficulties in treating severe complications and multi-organ failures underline the importance of prevention, ideally pretravel.
Typical patterns and key events identified in this study examined not only the travel period itself and the anti-malarial interventions used (mosquito bite protection, chemoprophylaxis) but primarily the period before and after travel, including the pre-travel communication between health care providers and travelers, the patient's post-travel handling of illness, the correct establishing or ruling out of the diagnosis, and the prompt treatment initiation. Interestingly, a recent American study examining malaria-related deaths among US travelers made equal or very similar observations as to how these deaths could have been prevented. 15 The study concluded that health care providers must educate travelers about malaria and keep in mind the importance of taking a travel history, obtaining a blood film for suspected malaria, and seeking expert advice. Furthermore, according to that study, hospitals in the United States should have intravenous quinidine gluconate on formulary because it is the only drug available to treat severe malaria in the United States. In our study, we did not observe any delay in treatment because of unavailability of therapeutic agents.
The two Swiss nationals who were infected in Switzerland died of airport malaria and transfusion-transmitted malaria, respectively. Those very rare cases usually have much higher CFRs, because the diagnosis is often excessively delayed because of the absence of a history of exposure to potentially malaria-infected mosquito bites. 16 Airport malaria occurs mainly in hot summers favoring the survival of the mosquitoes. Physicians should keep these possibilities in the back of their minds when treating patients with unclear fever or thrombocytopenia.
We conclude that imported falciparum malaria is still a frequent event in Switzerland and a challenge to travel health practitioners and general practitioners. The main group at high risk of death are non-immune Swiss and European nationals traveling as tourists to Africa. On the other hand, the numbers of falciparum cases is increased in travelers, mainly of African origin, who have settled in Switzerland and whose previously acquired semi-immunity has waned. Most infections with P. falciparum occur in Sub-Saharan Africa and can be attributed to an incorrect use or non-use of prophylactic measures. Despite increasing resistance, the three recommended drug regimens (mefloquine, atovaquone/proguanil, and doxycycline) are still highly effective in P. falciparumendemic areas. Travelers taking regular and recommended chemoprophylaxis do not appear in the group of fatal infections. Many travelers do not use chemoprophylaxis, possibly because of perceived adverse events or because they think that malaria is readily curable. Prevention strategies must try to reach these travelers. Travel operators and airlines can facilitate this process. The attention of both travelers and physicians should be raised even more to create a broad awareness of the disease. General practitioners play a decisive role before and after their patients travel to falciparumendemic areas. They should be aware of their importance in preventing fatalities caused by malaria and update regularly with the current and standardized information about drug recommendations to avoid confusion and folklore-based opinions among the travelers. Most important is providing individually tailored protection with concise advice on how to handle an eventual infection. General practitioners who see departing or returned travelers should not hesitate to draw on specialist advice if they are not familiar with malaria. Most important, post-travel is the advice to "think" malaria. Otherwise, a malarial infection can easily be missed or misdiagnosed, particularly in the influenza season. These patients may be unable to attend a follow-up visit if their condition has worsened. Once the suspicion is raised, microscopic diagnosis by an expert laboratory is required as soon as possible. One negative blood slide does not rule out falciparum malaria and has to be repeated within the next 12-24 hours. When expert laboratory analysis is negative or still delayed, physicians must begin antimalarial treatment if the clinical suspicion is high (summary of positive indicators like clinical presentation, travel history, positive rapid dip-stick test). If the condition of the patient is indicative of severe infection, hospital admission with specialist advice is imperative. The most important findings of our study regarding the role of the general practitioners have been put in the info box.
Further research on the knowledge, attitudes, and practices of travelers and general practitioners regarding malaria prevention and treatment is needed. What proportion of travelers to malaria endemic areas seek pre-travel advice and do not use the recommended chemoprophylaxis? What are the exact reasons for non-adherence? The role and protective effect of acquired semi-immunity needs clarification.. Kenya was the main destination for the travelers with fatal outcomes. Does this pinpoint Kenya as a main tourist destination of the Swiss residents or could it suggest a higher prevalence of mosquitoes/plasmodia or overly careless travel operators giving false advice in that region. The future role and applications for rapid diagnostic tests need further evaluation in the travel clinic setting. Currently, they serve as a useful tool but do not replace expert microscopy.
Reducing infections and fatalities among travelers is an achievable goal, and the attitudes and practices of both travelers and physicians need to be addressed. 
